✦ LIBER ✦

Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer

✍ Scribed by Paulo M. Hoff; Robert A. Wolff; Henry Xiong; Dennie Jones; Edward Lin; Cathy Eng; Ankhi Dutta; Karla R. Bogaard; James L. Abbruzzese

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 92 KB
Volume: 106
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21874

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combining capecitabine, oxaliplatin, and

Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial

✍ Se Hyun Kim; Sang Joon Shin; Sun Young Kim; Se Hoon Lee; Young Suk Park; Se Hoon 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 300 KB

Phase I/II trial of topotecan given as c

Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer

✍ G. Hütter; H. Szélenyi; P. M. Deckert; U. Keilholz; E. Thiel 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 191 KB

A phase I trial of S-1 with oxaliplatin

A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer

✍ Hyeong Su Kim; Min Jae Park; Ji Eun Uhm; Yuna Lee; Hui Young Lee; Eun Mi Kang; J 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 111 KB

A phase II study of irinotecan in combin

A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer

✍ Takeshi Kato; Hideyuki Mishima; Masakazu Ikenaga; Kouhei Murata; Hideyuki Ishida 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 259 KB

A Phase I study of raltitrexed and pacli

A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors

✍ Everett E. Vokes; Boon C. Goh; Donna Bertucci; Nicholas J. Vogelzang; Sridhar Ma 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

## BACKGROUND. Raltitrexed is a novel thymidylate synthase inhibitor with single agent activity in colorectal, nonsmall cell lung, and breast carcinomas. The recommended Phase II dose of raltitrexed administered as a single agent is 3 mg/m 2 every 3 weeks. Paclitaxel also has a broad spectrum of a

A phase II study of combination therapy

A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer

✍ Manabu Shiozawa; Makoto Akaike; Nobuhiro Sugano; Kazuhito Tsuchida; Naoto Yamamo 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 347 KB